1
|
Tyler DS, Stanley SD, Bartlett JA, Bolognesi DP, Weinhold KJ. Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs. J Surg Res 1998; 79:115-20. [PMID: 9758725 DOI: 10.1006/jsre.1998.5415] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Lymphocytes from HIV-1-seropositive and -seronegative individuals were examined to determine whether HIV-1 infection interfered with the ability to generate a lymphokine-activated killer (LAK) cell response. Following a 3-day ex vivo incubation in the presence of 1000 U/ml of recombinant interleukin-2, lymphocytes from seropositive individuals exhibited a LAK cell response which was equivalent to or greater than that of seronegative controls as measured against Daudi cell targets. LAK cells from seropositive and seronegative donors showed no specific cytolytic activity against gp120-coated or HIV-1-infected targets. However, in the presence of patient sera, significant levels of virus-specific LAK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) were observed. The level of this specific LAK cell-mediated ADCC was greater than that mediated under similar conditions by freshly isolated peripheral blood mononuclear cells. The greatest improvement in ADCC over baseline activity was seen with lymphocytes from AIDS patients after the 3-day ex vivo activation, suggesting that this patient population might benefit the most from adaptive LAK cell therapy.
Collapse
Affiliation(s)
- D S Tyler
- Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
| | | | | | | | | |
Collapse
|
2
|
Smyth MJ, Kershaw MH. Cytotoxic lymphocyte-mediated immunotherapy. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE 1995; 25:852-8. [PMID: 8770363 DOI: 10.1111/j.1445-5994.1995.tb02891.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Cytotoxic CD8+ T cells and NK cells play a role in the elimination of some viruses, graft rejection, antitumour responses, immunoregulation and some autoimmune diseases. The central importance of these cells in each of these immune responses and the therapeutic potential they offer, when effectively targeted, has justified continued interest in their function. Molecular biology has dominated the recent study of cytotoxic lymphocyte function, allowing the characterisation of recognition structures on cytotoxic lymphocytes, the definition of two distinct mechanisms of cytotoxicity and the determination of their relevance in vivo. Biological and genetic experimental approaches which exploit the targeted cytolytic activity of lymphocytes are now being developed for immunotherapy. A greater knowledge of the biology of cytotoxic lymphocytes when adoptively transferred, the development of engineered monoclonal antibodies and the characterisation of novel endogenous tumour cell antigens, has us on the brink of using these cells to greater therapeutic advantage. This article reviews ongoing efforts to characterise the mechanism of action of cytotoxic lymphocytes and outlines the progression of approaches designed to enhance the anti-tumour activity of these cells.
Collapse
Affiliation(s)
- M J Smyth
- Cellular Cytotoxicity Laboratory, Austin Research Institute, Austin Hospital, Melbourne, Vic
| | | |
Collapse
|
3
|
Eisenthal A, Skornick Y, Merimsky O, Hirsch R, Zakut V, Ron I, Chaitchik S. Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors. Cancer Immunol Immunother 1993; 37:233-9. [PMID: 8348562 PMCID: PMC11038831 DOI: 10.1007/bf01518516] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/1993] [Accepted: 05/20/1993] [Indexed: 01/30/2023]
Abstract
In the present study we demonstrate the ability of allogeneic M3 tumor cells to induce an antitumor response against the syngeneic tumor, when injected locally together with syngeneic B16 melanoma cells. The replacement of the allogeneic tumor cells with either syngeneic or allogeneic splenocytes had no effect on the growth of the syngeneic tumor. Systemic administration of both interleukin-2 (IL-2) and IL-6 did not affect the antitumor response induced by allogeneic tumor cells. When mice, previously injected with B16 and M3 cells, were rechallenged subcutaneously with B16 tumor cells at a different anatomical site, an inhibitory effect in some, but not all, experiments was observed. Systemic injections of either IL-2 or IL-6 did not alter the antitumor effects of the allogeneic and syngeneic tumor-cell mixtures. The significance of our results in developing immunotherapy modalities based on active immunization with allogeneic tumor cells and selected cytokines is discussed.
Collapse
Affiliation(s)
- A Eisenthal
- Oncology Institute, Tel-Aviv Sourasky Medical Center, Israel
| | | | | | | | | | | | | |
Collapse
|
4
|
Ramakrishna V, Eisenthal A, Skornick Y, Shinitzky M. Increased projection of MHC and tumor antigens in murine B16-BL6 melanoma induced by hydrostatic pressure and chemical crosslinking. Cancer Immunol Immunother 1993; 36:293-9. [PMID: 8477415 PMCID: PMC11038729 DOI: 10.1007/bf01741167] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/1992] [Accepted: 11/30/1992] [Indexed: 01/31/2023]
Abstract
The B16-BL6 melanoma, like most spontaneously arising tumors, is poorly immunogenic and expresses low levels of major histocompatibility complex (MHC) antigens. Treatment of cells of this tumor in vitro by hydrostatic pressure in the presence of adenosine 2',3'-dialdehyde (oxAdo), a membrane-impermeant crosslinker, caused elevated projection of MHC and a specific tumor antigen as demonstrated by flow-cytometric analysis. Maximum projection of both the MHC and the tumor antigens could be reached by application of 1200 atm for 15 min in the presence of 20 mM oxAdo. It is not yet clear whether this passive increase in availability of antigens on the cell surface originated from a dormant pool of antigens in the plasma membrane or from pressure-induced fusion of antigen-rich intracellular organelles (e.g. the endoplasmic reticulum). The immunogenic properties of the antigen-enriched B16-BL6 cells are described in the following paper.
Collapse
Affiliation(s)
- V Ramakrishna
- Department of Membrane Research and Biophysics, Weizmann Institute of Science, Rehovot, Israel
| | | | | | | |
Collapse
|
5
|
Eisenthal A, Kashtan H, Rabau M, Ramakrishna V, Chaitchik S, Skornick Y. Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells. Cancer Immunol Immunother 1993; 36:101-7. [PMID: 8425207 PMCID: PMC11038442 DOI: 10.1007/bf01754409] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/1992] [Accepted: 08/19/1992] [Indexed: 01/30/2023]
Abstract
In the present study we evaluate the antitumor efficacy of a glycosylated molecule of interleukin-6 (IL-6), which was cloned and expressed in Chinese hamster ovary cells. When tested with two syngeneic murine tumors, the MC38 adenocarcinoma and the MCA106 fibrosarcoma, recombinant IL-6 (rIL-6) significantly reduced the number of day-3 established MC38 lung metastases, but had no effect on MCA106 lung metastases. A similar effect of rIL-6 was seen on day-3 MC38 liver metastases. The antitumor activity mediated by rIL-6 was achieved at doses of the cytokine ranging from 6 micrograms to 150 micrograms/day. There was no correlation between the responsiveness to rIL-6 of these two tumors and their susceptibility, in vitro, to a direct cytostatic effect of the cytokine or the increase in the expression of major histocompatibility complex (MHC) antigens after exposure to rIL-6. However, a correlation was seen between the antitumor response to rIL-6 and the initial number of tumor cells expressing MHC antigens. The possible role of MHC antigens expressed on tumor cells, the generation of MHC-restricted cytotoxic cells and the responsiveness to IL-6 are discussed.
Collapse
Affiliation(s)
- A Eisenthal
- Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Israel
| | | | | | | | | | | |
Collapse
|
6
|
Vuist WM, Visseren MJ, Otsen M, Bos K, Vyth-Dreese FA, Figdor CG, Melief CJ, Hekman A. Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha. Cancer Immunol Immunother 1993; 36:163-70. [PMID: 8439976 PMCID: PMC11038052 DOI: 10.1007/bf01741087] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/1992] [Accepted: 10/20/1992] [Indexed: 01/30/2023]
Abstract
Antibody-dependent cellular cytotoxicity (ADCC) is regarded as an important mechanism by which monoclonal antibodies (mAb) can exert an antitumour effect in vivo. It may be possible, therefore, to enhance the therapeutic efficacy of mAb by cytokines that are able to enhance the ADCC of human CD3-, CD56+, CD16+ natural killer (NK) cells. We investigated in vitro the effects of recombinant interferon alpha (rIFN alpha) and recombinant interleukin 2 (rIL-2), alone or in combination, on the ADCC of human peripheral blood NK cells. Both cytokines enhanced the ADCC of the human effector cells. rIFN alpha induced a maximally increased ADCC after an exposure of human effector cells to 20 IU/ml for 15-30 min, while rIL-2 induced optimal ADCC after incubation of the cells for 2 days in 20-50 U/ml. We now show that activation of the NK cells with a combination of rIL-2 and rIFN alpha induced significantly higher levels of ADCC than either cytokine alone. The highest ADCC was induced if the cells were first exposed to rIL-2 before rIFN alpha was added to the culture. Culture of NK cells in medium or rIL-2 decreased the expression of Fc gamma RIII (CD16), indicating that intensity of CD16 expression and level of ADCC are not directly correlated, although blocking experiments with a mAb directed against CD16 showed that this Fc gamma R was essential for ADCC of the human effector cells.
Collapse
Affiliation(s)
- W M Vuist
- Division of Immunology The Netherlands Cancer Institute, Amsterdam
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Albertini MR, Hank JA, Sondel PM. Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2. BIOTHERAPY (DORDRECHT, NETHERLANDS) 1992; 4:189-98. [PMID: 1599802 DOI: 10.1007/bf02174205] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- M R Albertini
- Department of Human Oncology, University of Wisconsin, Madison 53792
| | | | | |
Collapse
|
8
|
Kato K, Agatsuma T, Tanabe T, Masuko T, Hashimoto Y. Release of esterase from murine lymphokine-activated killer cells in antibody-dependent cellular cytotoxic reaction. Jpn J Cancer Res 1991; 82:206-12. [PMID: 1900824 PMCID: PMC5918378 DOI: 10.1111/j.1349-7006.1991.tb01830.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Release of granule enzyme(s) (BLT esterase) in the antibody dependent lymphokine-activated killer (LAK) cell-mediated cytotoxic reaction (LAK ADCC) was studied using LAK cells induced from murine splenocytes and thymocytes, various human tumor cells and relevant monoclonal antibodies (mAbs) to the tumor cells. BLT esterase was not significantly released from LAK cells in direct LAK cell-mediated cytotoxic reactions (LAK CMC). However, cultures of LAK cells and IgG-coated target tumor cells resulted in release of the enzyme concomitantly with target cell lysis, although esterase release proceeded faster than target cell lysis. Anti-LFA-1 mAb showed an inhibitory effect on LAK CMC but not on either LAK ADCC or BLT esterase release in the ADCC. These results indicate that exocytosis of granule enzyme from LAK cells is triggered by stimulation of Fc receptor on LAK cells and that LAK CMC and LAK ADCC differ in their lytic mechanism in terms of the release of BLT esterase.
Collapse
Affiliation(s)
- K Kato
- Department of Hygienic Chemistry, Pharmaceutical Institute, Tohoku University, Sendai
| | | | | | | | | |
Collapse
|
9
|
Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49:281-355. [PMID: 1853786 DOI: 10.1016/s0065-2776(08)60778-6] [Citation(s) in RCA: 434] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- P D Greenberg
- Department of Medicine and Immunology, University of Washington, Seattle
| |
Collapse
|
10
|
Pendurthi TK, Parker R, Schlom J, Primus FJ. Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612. Int J Cancer 1990; 46:1021-8. [PMID: 2123477 DOI: 10.1002/ijc.2910460613] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The antibody-dependent cellular cytotoxicity (ADCC) properties of a murine monoclonal antibody (MAb), designated D612 (IgG2a), which reacts with human colon carcinomas, was studied using normal human peripheral blood lymphocytes (PBMNC). Although the level of ADCC of PBMNC with D612 varied among different donors, it was 20 to 30 times higher than the lytic activity of control cultures containing isotype-matched control MAb. Incubation of PBMNC with recombinant interleukin-2 (IL-2) resulted in a 2- to 5-fold augmentation in the cytotoxicity of effector cells exposed to MAb. This augmentation was apparent after subtracting nonspecific cellular cytotoxicity from the total cytotoxicity mediated by activated effector cells in the presence of D612. Optimal stimulation of specific ADCC with IL-2 appeared after 24 hr of culture in 500 U/ml of IL-2, resulting in a 3.8 +/- 1.7 fold increase in lytic units. However, stimulation of ADCC was also evident at 10 U/ml of IL-2. Furthermore, antibody dose titrations with untreated and IL-2 activated effectors showed that the threshold dose of MAb needed for efficient ADCC was reduced by 200-fold with IL-2. Depletion of FcR gamma III-positive lymphoid cells markedly reduced D612 ADCC, demonstrating the participation of NK/LAK cells in D612-mediated ADCC. Low levels of ADCC activity were found associated with adherent cells, either untreated or following their activation with gamma-interferon, while D612 was most active with non-adherent effectors. The specificity and ADCC properties of the D612 MAb suggest that it should be considered as a candidate for immunotherapy of colon cancer, particularly when used in combination with IL-2 plus LAK cell treatment.
Collapse
Affiliation(s)
- T K Pendurthi
- Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD 20892
| | | | | | | |
Collapse
|
11
|
Jenski LJ. Accessory molecules and antigen requirements for young and aging cytotoxic lymphocytes. Mech Ageing Dev 1990; 55:107-22. [PMID: 2232906 DOI: 10.1016/0047-6374(90)90019-c] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
In this study I have investigated whether young and aging alloreactive cytotoxic T-lymphocytes (CTL) have comparable antigen requirements, and whether the accessory molecules Ly2 and LFA-1 participate similarly in cytolysis mediated by young and old cells. Spleen and lymph node cells from young and aging, naive and primed mice were stimulated in bulk culture with allogeneic cells; cytotoxicity and proliferation were then measured. Additionally, lymph node cells were cultured under limiting dilution conditions, and the resultant clones here tested for cytotoxicity in the presence or absence of antibodies against Ly2 and LFA-1. I found that accessory molecules from naive and primed, young and aging splenic CTL participated similarly in cytolysis. However, both cytotoxic and proliferating splenic T-cells from aging mice required a greater alloantigen concentration for optimal response. Heterogeneous lymph node CTL from old mice demonstrated less cytotoxicity than young CTL, and, on the clonal level, old naive CTL clones were less active than young clones. Naive aging clones were more resistant than young clones to anti-Ly2 and anti-LFA-1. After priming, clone activity among the various age groups did not differ. These results suggest a qualitative difference between young and old cytolytic cells prior to alloantigen priming in vivo.
Collapse
Affiliation(s)
- L J Jenski
- Department of Biology, Indiana University-Purdue University, Indianapolis 46205
| |
Collapse
|
12
|
Eisenthal A. Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2. Cancer Immunol Immunother 1990; 31:342-8. [PMID: 2386979 PMCID: PMC11038655 DOI: 10.1007/bf01741405] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/1989] [Accepted: 03/26/1990] [Indexed: 12/31/2022]
Abstract
Prostaglandins can inhibit the generation of lymphokine-activated killer (LAK) cells by interleukin-2 (IL-2) whereas indomethacin augmented the induction of LAK cells by inhibiting prostaglandin synthesis. In the present study we demonstrate that prostaglandin E2 substantially inhibited the generation of both LAK and antibody-dependent cellular cytotoxicity (ADCC) activity by IL-2. In addition, indomethacin enhanced the induction of LAK activity and ADCC in splenocytes exposed to IL-2 in vitro. The effect of indomethacin was dose-dependent, reaching an optimal effect at 1 microM when 100-1000 units/ml IL-2 were employed. The effect of indomethacin on the generation of ADCC was seen in cells taken from both tumor-bearing mice and normal mice. ADCC induced by IL-2 was augmented by culturing cells from the spleen, liver and lungs, in the presence of indomethacin. ADCC induced in the presence of IL-2 and indomethacin was mediated by cells that were mainly plastic non-adherent cells and expressed the asialo-GM1 glycolipid. The potential of indomethacin in combined therapy with cytokines and specific anti-tumor monoclonal antibodies is discussed.
Collapse
Affiliation(s)
- A Eisenthal
- Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
| |
Collapse
|
13
|
Eisenthal A, McIntosh JK. Effect of recombinant human tumor necrosis factor alpha on the induction of antibody-dependent cellular cytotoxicity in the treatment of established B16 melanoma liver nodules. Cancer Immunol Immunother 1990; 31:243-9. [PMID: 2379220 PMCID: PMC11038147 DOI: 10.1007/bf01789176] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/1989] [Accepted: 01/10/1990] [Indexed: 12/31/2022]
Abstract
Incubation of C3H/Hen thymocytes in the presence of recombinant human tumor necrosis factor alpha (TNF) and interleukin-2 (IL-2) augmented the generation of antibody-dependent cellular cytotoxicity (ADCC) when compared to cells cultured in TNF or IL-2 alone. This effect was optimal when 100-200 units/ml IL-2 was used together with 10(3)-10(4) units/ml TNF. TNF alone at any concentration could not mediate the induction of ADCC. Similar to the results obtained in vitro, TNF, when given alone, had no effect on the generation of ADCC in vivo. The addition, however, of TNF to IL-2, given at 10,000 and 20,000 but not 40,000 units, enhanced the IL-2-induced ADCC on a per-cell basis. Furthermore, TNF enhanced the total ADCC activity in various organs including the liver, spleen and thymus as a result of an increase in the number of mononuclear cells isolated from these organs. The increase in total ADCC activity was optimal when 110,000-220,000 units (5-10 micrograms) TNF were employed together with IL-2. The combined treatment with TNF and IL-2 also increased the intracellular benzyloxycarbonyl-1-L-lysine-thiobenzyl-ester esterase content in cells isolated from the livers of mice treated with these cytokines. On the basis of these results we treated mice bearing a single B16 melanoma nodule with TNF and TNF + IL-2 given with or without anti-B16 monoclonal antibody. We found that TNF administration augmented the anti-tumor effect of specific anti-B16 antibodies, and the addition of IL-2 further increased this anti-tumor effect.
Collapse
Affiliation(s)
- A Eisenthal
- Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
| | | |
Collapse
|
14
|
Lala PK. Similarities between immunoregulation in pregnancy and in malignancy: the role of prostaglandin E2. Am J Reprod Immunol 1989; 20:147-52. [PMID: 2696481 DOI: 10.1111/j.1600-0897.1989.tb00987.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Affiliation(s)
- P K Lala
- Department of Anatomy, University of Western Ontario, London, Canada
| |
Collapse
|